Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 62Neoplasms 52Neoplasm Metastasis 49Leukemia, Myeloid, Acute 48Colorectal Neoplasms 48Breast Neoplasms 44Prostatic Neoplasms 38Multiple Myeloma 34Ovarian Neoplasms 32Recurrence 29Melanoma 28Pancreatic Neoplasms 27Lymphoma, Non-Hodgkin 26Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Endometrial Neoplasms 22Triple Negative Breast Neoplasms 21Glioblastoma 20Carcinoma, Renal Cell 20Lung Neoplasms 19Advanced Solid Tumors 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, B-Cell 14Esophageal Neoplasms 13Advanced Solid Tumor 13

Interventions

radium Ra 223 dichloride 1darolutamide 1Radium-223 1Nivolumab 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Cancer × 30 days × Clear all
NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06492122 2026-05-26

ProTACT

Full-Life Technologies GmbH

Phase 1 Recruiting
50 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06052306 2026-05-18

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Bayer

Phase 1 Active not recruiting
232 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07244341 2026-05-15

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡